Sort   by:  
 Page size 
Hemophilia B, or the 'Royal Disease', arises from mutations in the Coagulation Factor IX (F9) gene. Mutations within the F9 promoter are associated with a remarkable form of the disease, termed Hemophilia B Leyden, in which symptoms ameliorate after puberty. Mutations at the -5/-6 site account for t...
ORGANISM(S): Mus musculus 
Background: The main complication in hemophilia A treatment is the development of inhibitory antibodies against factor (F)VIII. Immune tolerance induction, the gold standard for eradicating anti-FVIII antibodies, is efficient in only 60% to 80% of cases. This underscores the need for more efficient in...
ORGANISM(S): Homo sapiens (Human) 
2025-10-02 | PXD069058 | Pride
To investigate the gene expression in dendritic cells after treating hemiphilic mice with HBSS, plasma derived or recombinant factor VIII Gene expression in dendritic cells were measured 24 hours post treatment Hemophilic mice with treated with either (HBSS, rFVIII or pdFVIII) 24 hours post treatmen...
ORGANISM(S): Mus musculus 
Hemophilia A (HA) is a bleeding disorder caused by deficiency of functional plasma clotting factor VIII (FVIII). In addition to genetic mutations in the gene encoding FVIII (F8), there is evidence that other molecular mechanisms may be involved in the pathobiology of HA. In this study, global small ...
ORGANISM(S): Homo sapiens 

Rare individuals are highly resistant to infection with human immunodeficiency virus (HIV). Studies of candidate genes resulted in the discovery of a 32bp deletion in the CC-chemokine receptor 5 gene (CCR5Δ32), which rendered this critical co-receptor for primary HIV infection to be non-func...

Multicenter Hemophilia Cohort Studies (MHCS-BioLINCC)
Multicenter Hemophilia Cohort Studies (MHCS-BioLINCC)
Sort   by:  
 Page size